Program
apalutamide
Also written as “Apalutamide”, “JNJ-56021927” and “ARN-509”.
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Salivary Gland Neoplasms, led by 2 companies.
Drug pageApalutamide: every studyAll 85 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 2711 open or running | phase 4since Sep 26, 2019 | Jul 27, 2010 | Dec 1, 2026phase 3 · NCT03767244 |
| Sumitomo Pharmaits history only | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
Also a collaborator on its studies: Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 12 earlier studies, Jul 27, 2010 to Jul 1, 2015.
- Jun 9, 2015Named apalutamideINNProposed as its International Nonproprietary Name in WHO's List 113 · before, JNJ-56021927, ARN-509, JNJ 56021927
- Aug 13, 2015Phase 1 study in Hepatic ImpairmentNCT02524717 · 24 enrolled · United States
- Aug 21, 2015Phase 3 study in Prostatic NeoplasmsNCT02531516 · 1,503 enrolled · United States, Argentina, Belgium and more
- Oct 15, 20152 phase 1 studiesNCT02578797, NCT02592317
- Jun 29, 2016Phase 1 study in HealthyNCT02835508 · 18 enrolled · Japan
- Sep 15, 2016Phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT02906605 · United States
- Oct 4, 2016Phase 1 study in Prostatic NeoplasmsNCT02924766 · 34 enrolled · United States, Canada
- May 2, 2018Phase 1 study in Prostatic NeoplasmsNCT03523442 · 19 enrolled · China
- Dec 5, 2018Phase 3 study in Prostatic NeoplasmsNCT03767244 · 2,517 enrolled · United States, Argentina, Australia and more
- Jan 11, 2019Phase 1 study in HealthyNCT03802682 · 12 enrolled · Belgium
- Sep 26, 2019Phase 4 study in Prostatic NeoplasmsNCT04108208 · 75 enrolled · China
- Nov 5, 2019Phase 1 study in Hepatic ImpairmentNCT04154774 · 18 enrolled · United States
- Mar 26, 2020Phase 2 study in Salivary Gland NeoplasmsNCT04325828 · 31 enrolled · Japan
- Sep 17, 2020Phase 3 study in Prostatic NeoplasmsNCT04557059 · 691 enrolled · United States, Australia, Austria and more
- May 23, 2023Phase 3 study in Metastatic Castrate-sensitive Prostate CancerNCT05884398 · 420 enrolled · United States, Australia, Brazil and more
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Prostatic NeoplasmsNCT03767244
- Mar 1, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT02531516
- Aug 27, 2029Primary completion: phase 3 study in Prostatic NeoplasmsNCT04557059
TargetBeta
“A small molecule and androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 27 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05884398Metastatic Castrate-sensitive Prostate Cancer · United States, Australia, Brazil and more | 3 | Active, not recruiting | Oct 12, 2026 | 420 |
| NCT04557059Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Aug 27, 2029 | 691 |
| NCT04325828Salivary Gland Neoplasms · Japan | 2 | Active, not recruiting | Jun 9, 2021 | 31 |
| NCT04154774Hepatic Impairment · United States | 1 | Completed | Feb 10, 2025 | 18 |
| NCT04108208Prostatic Neoplasms · China | 4 | Completed | Jun 1, 2023 | 75 |
| NCT03802682Healthy · Belgium | 1 | Completed | Apr 11, 2019 | 12 |
| NCT03767244Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 1, 2026 | 2,517 |
| NCT03523442Prostatic Neoplasms · China | 1 | Active, not recruiting | Jul 9, 2019 | 19 |
| NCT02924766Prostatic Neoplasms · United States, Canada | 1 | Completed | Jul 18, 2019 | 34 |
| NCT02906605Prostatic Neoplasms, Castration-Resistant · United States | 2 | Withdrawn | Sep 2018 | 0 |
| NCT02835508Healthy · Japan | 1 | Completed | Dec 2016 | 18 |
| NCT02592317Prostatic Neoplasms, Castration-Resistant · Moldova, Spain | 1 | Active, not recruiting | Nov 7, 2016 | 23 |
| NCT02578797Prostatic Neoplasms · United States, Canada, Moldova, Republic of and more | 1 | Completed | Sep 20, 2016 | 45 |
| NCT02531516Prostatic Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Mar 1, 2027 | 1,503 |
| NCT02524717Hepatic Impairment · United States | 1 | Completed | Feb 9, 2017 | 24 |
| NCT02489318Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 7, 2020 | 1,052 |
| NCT02257736Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 19, 2018 | 982 |
| NCT02230033Healthy · United States | 1 | Completed | Dec 2014 | 45 |
| NCT02162836Prostatic Neoplasms, Castration-Resistant · Japan | 1 | Completed | May 27, 2019 | 6 |
| NCT02160756Healthy | 1 | Completed | Nov 2014 | 75 |
| NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more | 1 | Active, not recruiting | Jun 27, 2016 | 57 |
| NCT02031666Healthy · United States | 1 | Completed | Apr 2014 | 120 |
| NCT01946204Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | May 19, 2017 | 1,207 |
| NCT01822041Healthy · Netherlands | 1 | Completed | Jun 2013 | 12 |
| NCT01792687Prostatic Neoplasms · United States | 1 | Completed | May 10, 2014 | 6 |
| NCT01790126Prostatic Neoplasms · United States | 2 | Completed | Mar 1, 2019 | 90 |
| NCT01171898Prostatic Neoplasms · United States | 2 | Completed | Aug 20, 2012 | 127 |
How it is read
Names in the registry
- “Apalutamide”, 18 entries
- “JNJ-56021927”, 4 entries
- “ARN-509”, 3 entries
- “JNJ 56021927”, 1 entry
- “apalutamide”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 19 studies
- Prostatic Neoplasms, Castration-Resistant, 3 studies
- Salivary Gland Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.